Blood Pressure Targets in Acute Ischemic vs Hemorrhagic Stroke
Blood pressure management differs fundamentally between ischemic and hemorrhagic stroke: in acute ischemic stroke, permissive hypertension is the default approach (avoiding BP lowering unless >220/120 mmHg), while in acute intracerebral hemorrhage, early aggressive reduction to systolic BP <140 mmHg is recommended to limit hematoma expansion. 1
Acute Ischemic Stroke: Permissive Hypertension Strategy
Without Reperfusion Therapy
Avoid routine BP lowering in the first 24 hours unless systolic BP exceeds 220 mmHg or diastolic BP exceeds 120 mmHg. 1 The rationale is that elevated BP may maintain cerebral perfusion to ischemic penumbra, and aggressive lowering has not demonstrated benefit for mortality or functional outcomes. 2
When BP exceeds 220/120 mmHg:
- Reduce BP cautiously by <15% within 24 hours
- No specific antihypertensive agent is recommended over others 1
With Intravenous Thrombolysis
Maintain BP <185/110 mmHg before thrombolytic bolus, then <180/105 mmHg during and for 24 hours after treatment. 1 This strict threshold exists to minimize hemorrhagic transformation risk.
Do NOT target intensive lowering to 130-140 mmHg during the first 72 hours, as this provides no additional benefit. 1
With Mechanical Thrombectomy
Keep BP <180/105 mmHg during and for 24 hours after the procedure. 1
Critical caveat: After successful reperfusion (mTICI grade 3), strongly avoid actively reducing systolic BP <140 mmHg in the first 24 hours (high-certainty evidence, strong recommendation against). 1 This intensive lowering likely increases mortality and reduces favorable neurologic outcomes. 2
Avoid systolic BP drops during the procedure, and do not use vasopressors for induced hypertension. 1
Acute Intracerebral Hemorrhage: Aggressive Early Control
Reduce systolic BP to <140 mmHg as rapidly as possible after hospital presentation in patients with small-to-moderate hematomas. 1 This represents expert consensus despite uncertain net clinical benefit in trials, as the goal is to limit hematoma expansion—a key driver of mortality and disability. 3
Key Differences from Ischemic Stroke:
- Timing: Initiate BP lowering immediately upon ICH diagnosis, not delayed 3
- Target: Systolic BP <140 mmHg (vs. permissive hypertension in ischemic stroke) 1
- Rationale: Prevent hematoma expansion rather than maintain perfusion 3
Important Caveats:
- Avoid excessive BP drops or large variability 4
- Exercise particular caution when baseline systolic BP >220 mmHg 4
- Continue oral antihypertensives if patient can swallow; use IV agents if not 1
- Preferred IV agents include urapidil or labetalol (avoid transdermal glyceryl trinitrate) 1
Pre-Hospital Management
Do not lower BP in the ambulance for suspected stroke until brain imaging confirms stroke type. 1 This strong recommendation exists because treatment differs dramatically between ischemic and hemorrhagic stroke, and pre-hospital lowering may harm ICH patients.
Comparative Summary Table
| Parameter | Acute Ischemic Stroke | Acute Intracerebral Hemorrhage |
|---|---|---|
| Default approach | Permissive hypertension | Early aggressive lowering |
| Target (no reperfusion) | Avoid lowering unless >220/120 | <140 mmHg systolic |
| Target (with reperfusion) | <180/105 mmHg | N/A |
| Timing | Delay 24h unless extreme elevation | Immediate upon diagnosis |
| Post-successful thrombectomy | Avoid <140 mmHg (strong) | N/A |
| Rationale | Maintain penumbral perfusion | Limit hematoma expansion |
Evidence Quality and Certainty
The 2025 ESO guidelines 1 acknowledge that most recommendations carry moderate to very low certainty evidence due to inconsistent trial results and methodological limitations. The strongest evidence (high-certainty) supports avoiding intensive BP lowering <140 mmHg after successful thrombectomy. 1 For ICH, despite multiple trials, the net clinical benefit of intensive lowering remains uncertain, making the <140 mmHg target an expert consensus recommendation rather than evidence-based mandate. 1
Recent meta-analysis 2 confirms that intensive BP management in reperfused ischemic stroke results in little to no difference in clinical function but probably increases all-cause mortality (moderate-certainty evidence), reinforcing the permissive approach.